Professor David Jackson: key facts
- Kind of voice
- Clinician
- Role
- clinical lead of the asthma services at Guy's and St Thomas' NHS Foundation Trust and professor of respiratory immunology at King's College London
- Quoted on
- Respiratory (asthma/COPD)
- Press citations held
- 2
- Most recently quoted
- 10 Sept 2026
“As tezepelumab also suppresses allergy-related symptoms and improves chronic rhinosinusitis as well, the results are particularly exciting for patients with severe asthma who suffer with both upper and lower airway symptoms.”
What Professor David Jackson has said
“In this International, multicentre clinical trial of more than 300 patients, the NICE-approved asthma treatment tezepelumab, a biologic therapy that targets asthma-related inflammation but without all the side effects of steroids, was capable of allowing the vast majority of patients to wean their steroids down to a low dose with over half able to stop their steroids altogether.”
clinical lead of the asthma services at Guy's and St Thomas' NHS Foundation Trust and professor of respiratory immunology at King's College London · Respiratory (asthma/COPD) · 10 Sept 2026 · Half of severe asthma patients started on tezepelumab able to stop oral steroids ↗
Where Professor David Jackson has been quoted
- Severe asthma can be controlled by a monthly injection, trial findstheguardian.com · 10 Sept 2026
- Half of severe asthma patients started on tezepelumab able to stop oral steroidspulsetoday.co.uk · 10 Sept 2026
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.